Lentine Receives Award of Merit for Outstanding Contributions to Scientific Medicine
Krista Lentine, M.D., Ph.D., professor of medicine at Saint Louis University’s School of Medicine, is the 2024 recipient of the St. Louis Metropolitan Medicine Society Award of Merit for Outstanding Contributions to Scientific Medicine.
Krista Lentine, M.D., Ph.D. Photo by Sarah Conroy.
Lentine is vice chair of internal medicine research, associate division director of nephrology, and medical director of living donation. Lentine is a widely recognized leader in nephrology and transplant medicine, with a career dedicated to improving kidney transplantation outcomes and advancing research in organ donation and recipient care.
“Dr. Lentine’s research and leadership in transplantation have improved patient outcomes and shaped the future of kidney donation and recipient care. Her dedication to advancing scientific medicine in St. Louis and beyond makes her a deserving recipient of this honor,” said SLMMS 2024 President Kirsten Dunn, M.D, in St. Louis Metropolitan Medicine Magazine.
St. Louis Metropolitan Medicine Society (SLMMS) was formed in 1836 and is one of the oldest medical societies in the U.S. The award, first established in 1927, recognizes distinguished and exceptional service to scientific medicine in the greater St. Louis community. Over nearly a century, only 40 individuals have received this prestigious honor.
Lentine was recognized at the group’s annual meeting earlier this year.
Throughout her career Lentine has been instrumental in shaping policies and guidelines for living kidney donation and transplantation, serving on the Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) Living Donor Committee, where she held the role of chair, and as director of the Scientific Registry of Transplant Recipients (SRTR) Living Donor Collective.
Her research is centered on critical patient-centered themes, including understanding disparities in living-donor and transplant-patient outcomes; developing tools for tailored risk prediction; improving access to transplantation and organ use, especially for under-represented persons; and reducing consequences of comorbidities such as cardiovascular disease in transplant patients.
Latest Newslink
- Demchenko Named American Chemical Society FellowAlexei Demchenko, Ph.D., chemistry department chair, has been named an American Chemical Society Fellow for 2025. ACS fellows are members of the society who have "shown outstanding achievements in and contributions to science, the chemistry profession, and the society." This year, 36 members were named.
- James H. Korn, Ph.D.: 1938-2025James H. Korn, Ph.D., emeritus professor of psychology, died July 17, 2025. He was 87. Korn was a long-time professor at SLU. In 2006, the University established the James H. Korn Scholarship of Teaching and Learning Award in recognition of his many contributions to the research on teaching and learning.
- New Full-Time Faculty Members Join Saint Louis UniversitySaint Louis University has many new full-time faculty members joining the University this year. Check out the list of who is new at SLU.
- SLU Welcomes Home Newest Billikens at ConvocationThe newest Billikens, including new President Edward Feser, Ph.D., took part in the New Student Convocation and Family Welcome on Saturday morning inside Chaifetz Arena. The ceremony is designed to be one of the first opportunities for the new class of Billikens to develop a sense of cohesion and identity. Members of the SLU community shared how they serve a higher purpose and seek the greater good.
- SLU Doctoral Student Connects Ugandan Students With Pianos, Other Musical InstrumentsFr. Thomas Sserwadda, a doctoral student studying higher education administration at Saint Louis University, sent musical instruments to the Bukalasa Minor Seminary in Masaka Diocese, Uganda.
- SLU's New Venture Accelerator to Hold Demo Day Event August 14The Chaifetz Center for Entrepreneurship at Saint Louis University is hosting its second New Venture Accelerator (NVA) Demo Day on Thursday, Aug. 14. At the event, the cohort of AlgaEarth, Med Reveal, Phoenix Biomedical and Spray X will make final pitches to potential investors and partners interested in the future growth of the four companies.
